TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Patients could pay as little as a $15 copay for their prescription, with commercial insurance. Eligibility and limitations apply*

*ELIGIBILITY & LIMITATIONS: Eligible patients may receive TAVALISSE at a $15 copay for each prescription, if they pay through commercial insurance.
  • Patients must have a valid prescription for TAVALISSE and commercial insurance.
  • Patient must be 18 years of age or older.
  • This offer is not valid for prescriptions reimbursed under Medicare, Medicaid, TriCare or any other federal or state program, or where prohibited by law.
  • The patient will be responsible for any out-of-pocket expenses after the $25,000 annual cap.
  • This offer is not insurance and offer is valid only for prescriptions filled in the United States and Puerto Rico.
  • Not valid for cash-paying patients.
  • Rigel reserves the right to rescind, revoke, or amend this program without notice.
  • Other restrictions may apply. Patient is responsible for applicable taxes, if any.